Simulands

About Simulands

Simulands AG is a Zurich-based company operating in the medical device and healthcare training market, specifically focusing on the structural heart and cardiovascular sector. Founded in 2019 by a group of clinicians, engineers, and entrepreneurs, the firm addresses the need for more practical and ethical training solutions for complex cardiac procedures. This founding team, which includes CEO Andrea Guidotti, COO Luca Vicentini, and CFO Giuseppe Vita, identified limitations in traditional training methods, including animal research, and sought to provide a viable alternative.

The company develops, produces, and distributes physical simulators for cardiovascular interventions. These platforms are designed to be of clinical and technical equivalence to human cardiovascular systems, meeting ISO, CE, and FDA benchmarks. The simulators are created using additive manufacturing techniques and materials that replicate pathological anatomies, allowing for hands-on procedural training with real medical devices and imaging guidance. Key features include realistic tactile responses and compatibility with actual procedural imaging, which provides a high-fidelity training experience for cardiologists and echocardiographers.

Simulands' business model targets medical technology companies and teaching hospitals. It generates revenue by selling its simulators to these institutions for physician training and the internal education of their field specialists. Prominent clients include major medtech firms like Abbott Laboratories, Boston Scientific, and Edwards Lifesciences. In early 2023, the company secured €10 million in a funding round led by SHS Capital, a healthcare-focused private equity firm. This capital is intended to accelerate commercialization, expand the product portfolio, and support international growth. More recently, in January 2025, Simulands partnered with Abbott to open a cardiovascular training center in Germany, featuring its advanced simulation technology.